ScholarIQanswers from OpenAlex & ORCID
William F. Keane
ResearcherPublications, citations & collaboration network
William F. Keane is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does William F. Keane have?
ScholarIQindexed works
William F. Keane has 240 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does William F. Keane have?
ScholarIQcitation count
William F. Keane has 35,836 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of William F. Keane?
ScholarIQh-index
William F. Keane has an h-index of 67 in OpenAlex.
What is the i10-index of William F. Keane?
ScholarIQi10-index
William F. Keane has an i10-index of 163 in OpenAlex.
What is the OpenAlex record for William F. Keane?
ScholarIQopenalex
The OpenAlex for William F. Keane is on the source record.
What are the most-cited papers on William F. Keane?
ScholarIQmost cited works
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
Andrew S. Levey, Josef Coresh, Kline Bolton, Bruce F. Culleton, Kathy Schiro Harvey, T. Alp İkizler, Cynda Ann Johnson, Annamaria Kausz, Paul L. Kimmel, John W. Kusek, Adeera Levin, Kenneth L. Minaker, Robert G. Nelson, Helmut G. Rennke, Michael W. Steffes, Beth Witten, Ronald J. Hogg, Susan L. Furth, Kevin V. Lemley, Ronald J. Portman, George J. Schwartz, Joseph Lau, Ethan M. Balk, Ronald D. Perrone, Tauqeer Karim, Lara Rayan, Inas Al-Massry, Priscilla Chew, Brad C. Astor, Deirdre De Vine, Garabed Eknoyan, Nathan W. Levin, S Burrows-Hudson, William F. Keane, Alan S. Kliger, Derrick L. Latos, Donna Mapes, Edith T. Oberley, Kerry Willis, George R. Bailie, Gavin J. Becker, Jerrilynn D. Burrowes, David Churchill, Alan Collins, William Couser, Dick de Zeeuw, Alan J. Garber, Thomas A. Golper, Frank A. Gotch, Antonio M. Gotto, Joel Greer, Richard H. Grimm, Ramon G. Hannah, Jaime Herrera Acosta, Ronald J. Hogg, Lawrence G. Hunsicker, Michael J. Klag, Saulo Klahr, C. Lewis, Edmund G. Lowrie, Arthur Matas, Sally D. McCulloch, Maureen Michael, Joseph V. Nally, John M. Newmann, Allen R. Nissenson, Keith C. Norris, William F. Owen, Thakor G. Patel, Glenda M. Payne, Rosa A. Rivera-Mizzoni, David L. Smith, Robert A. Star, Theodore I. Steinman, Fernando Valderrábano, John Walls, Jean Pierre Wauters, Nanette K. Wenger, Josephine P. Briggs
Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy
Barry M. Brenner, Mark E. Cooper, Dick de Zeeuw, William F. Keane, William E. Mitch, Hans‐Henrik Parving, Giuseppe Remuzzi, Steven Snapinn, Zhonxin Zhang, Shahnaz Shahinfar
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL
Dick de Zeeuw, Giuseppe Remuzzi, Hans‐Henrik Parving, William F. Keane, Zhongxin Zhang, Shahnaz Shahinfar, Steve Snapinn, Mark E. Cooper, William E. Mitch, Barry M. Brenner
Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy
Dick de Zeeuw, Giuseppe Remuzzi, Hans‐Henrik Parving, William F. Keane, Zhongxin Zhang, Shahnaz Shahinfar, Steve Snapinn, Mark E. Cooper, William E. Mitch, Barry M. Brenner
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study
William F. Keane, Barry M. Brenner, Dick de Zeeuw, Jean‐Pierre Grünfeld, Janet B. McGill, William E. Mitch, Artur Beltrame Ribeiro, Shahnaz Shahinfar, Roger L. Simpson, Steven Snapinn, Robert D. Toto, RENAAL Study Investigators